22nd Dec. - Pfizer Ltd. confident that they will not have problems in meeting the demand for the Covid-19 vaccine and confident that the number of vaccines produced will exceed the required number by the end of 2021.
Demand for vaccines invented by the company is growing. Most recently, the United Kingdom government approved the use of vaccines created by Pfizer and their partner BioNTech. Demand for this vaccine increased after both companies were confident that it would be 95% effective in fighting the global Covid-19 virus by 2020.
Pfizer's share price has fallen over the past few weeks due to the expected short-term demand, instead it is just a more cautious and wait-and-see demand by some countries in addition to the emergence of other biotechnology companies such as Moderna Ltd and AstraZeneca.
Expected share price of Pfizer Ltd. has the potential to soar from time to time due to the increasing demand by various countries at this time. Pfizer Ltd. is expected to receive annual sales of around $ 40.8 to $ 42.4 billion.
AHMAD FAIZUDDIN BIN RAZALI
CHIEF ANALYST OF CDG GLOBAL
PFIZER LTD IS CONFIDENT THAT THE SUPPLY OF COVID-19 VACCINE IS SUFFICIENT TO MEET THE DEMAND
ACCESS THE FINANCIAL MARKETS ONLINE ANYWHERE ANYTIME
It takes a few minutes to enter the exciting world of trading
FED Meeting Minutes Published This Week, Dollar Strengthening Pauses
Markets This Week: Stock Markets Will Continue To Be Turbulent, US Dollar Strengthens And Gold Prices Possibly Continue To Plunge
The Current U.S. Inflation Rate Is The Main Focus of The Market This Week
Asian Stocks Strengthen, Japan’s Economy Contracts in First Quarter of 2021